Connor, Clark & Lunn Investment Management (CC&L)
KIN

Connor, Clark & Lunn Investment Management (CC&L)’s Kindred Biosciences, Inc. KIN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,351
Closed -$71K – 1146
2019
Q3 		$71K Sell
10,351
-12,777
-55% -$93.7K ﹤0.01% 928
2019
Q2 		$193K Sell
23,128
-14,921
-39% -$129K ﹤0.01% 906
2019
Q1 		$349K Sell
38,049
-20,226
-35% -$205K ﹤0.01% 726
2018
Q4 		$638K Sell
58,275
-2,300
-4% -$29K ﹤0.01% 648
2018
Q3 		$845K Sell
60,575
-5,000
-8% -$67.7K ﹤0.01% 596
2018
Q2 		$698K Sell
65,575
-10,200
-13% -$99.5K ﹤0.01% 698
2018
Q1 		$655K Sell
75,775
-2,600
-3% -$22.8K ﹤0.01% 532
2017
Q4 		$741K Sell
78,375
-2,500
-3% -$19.5K ﹤0.01% 563
2017
Q3 		$635K Buy
80,875
+2,000
+3% +$15K ﹤0.01% 602
2017
Q2 		$678K Buy
78,875
+8,250
+12% +$59.2K ﹤0.01% 553
2017
Q1 		$498K Buy
70,625
+4,700
+7% +$29.4K ﹤0.01% 629
2016
Q4 		$280K Buy
65,925
+2,400
+4% +$11.6K ﹤0.01% 730
2016
Q3 		$316K Buy
63,525
+800
+1% +$3.38K ﹤0.01% 665
2016
Q2 		$222K Buy
62,725
+350
+0.6% +$1.29K ﹤0.01% 729
2016
Q1 		$215K Sell
62,375
-5,700
-8% -$20.1K ﹤0.01% 705
2015
Q4 		$231K Buy
68,075
+4,075
+6% +$18.9K ﹤0.01% 684
2015
Q3 		$333K Buy
64,000
+14,300
+29% +$88.2K ﹤0.01% 585
2015
Q2 		$339K Buy
49,700
+1,900
+4% +$13.5K ﹤0.01% 474
2015
Q1 		$341K Buy
47,800
+12,500
+35% +$86.2K ﹤0.01% 442
2014
Q4 		$263K Buy
+35,300
New +$299K ﹤0.01% 482

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s KIN Position: Q4 2019 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Kindred Biosciences, Inc. (KIN) in Q4 2019, closing a stake of 10,351 shares — an estimated $71K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in KIN in Q4 2014 and held it in 20 quarters. The position peaked at $845K in Q3 2018. 75 funds tracked by Wall St. Rank hold KIN as of Q4 2019.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Kindred Biosciences, Inc. position as of Q4 2019 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 10,351 Kindred Biosciences, Inc. shares in Q4 2019, an estimated $71K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Kindred Biosciences, Inc. in Q4 2014 and held it in 20 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Kindred Biosciences, Inc. position peaked at $845K in Q3 2018.
  • 75 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q4 2019.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2019, filed 12 Feb 2020.